BioArctic AB’s partner Eisai announced that the results of a detailed analysis of the Phase 3 Clarity AD study, presented at the Alzheimer’s Association International Conference 2023, demonstrated that lecanemab-irmb treatment showed benefits on both amyloid-beta and tau pathology as well as other downstream biomarker changes.
